Differential regulation of caspase-3 by pharmacological and developmental stimuli as demonstrated using humanised caspase-3 mice

Apoptosis

Volumn 9, Issue 6, 2004, Pages 739-747

  Kerr, L E ^a   Birse Archbold, J L A ^a   Simon, A ^a   Logan, N ^a   Scott, F ^a   Carlson, G ^a   Nicholson, D W ^b   Kelly, J S ^a   Sharkey, J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apoptosis; Caspase 3; Development; Fas; Humanised mice

Indexed keywords

CASPASE 3; FAS ANTIGEN; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, MOUSE; CASPASE;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DEVELOPMENT; CELL DEATH; CONTROLLED STUDY; EMBRYO DEVELOPMENT; ENZYME DEGRADATION; ENZYME REGULATION; FRONTAL CORTEX; GENE DISRUPTION; GENETIC ANALYSIS; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; WESTERN BLOTTING;

MURINAE; MUS MUSCULUS;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL DEATH; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; TISSUE DISTRIBUTION;

EID: 21644483357     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:APPT.0000045787.50848.e1     Document Type: Article

References (47)

1. Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 1999; 6: 1028-1042.
2. Slee EA, Adrain C, Martin SJ. Executioner caspases-3, -6 and -7 perform distinct, non-redundant, roles during the demolition phase of apoptosis. J Biol Chem 2001; 276: 7320-7326.
3. Hara H, Friedlander RM, Gagliardini V, et al. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA 1997; 94: 2007-2012.
4. Endres M, Namura S, Shimizu-Sasamata M, et al. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab 1998; 18: 238-247.
5. Shimohama S, Tanino H, Fujimoto S. Changes in caspase expression in Alzheimer's disease: Comparision with development and aging. Biochem Biophys Res Commun 1999; 256: 381-384.
6. Stadelmann C, Deckwerth TL, Srinivasan A, et al. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol 1999; 155: 1459-1466.
7. Masumura M, Hata R, Nishimura I, Uetsuki T, Sawada T, Yoshikawa K. Caspase-3 activation and inflammatory responses in rat hippocampus inoculated with a recombinant adenovirus expressing the Alzheimer amyloid precursor protein. Mol Brain Res 2000; 80: 219-227.
8. Miyashita T, Matsui J, Ohtsuka Y, et al. Expression of extended polyglutamine sequentially activates initiator and effector caspases. Biochem Biophys Res Commun 1999; 257: 724-730.
9. Sanchez-Mejia RO, Friedlander RM. Caspases in Huntington's disease. Neuroscientist 2001; 7: 480-489.
10. Yakovlev AG, Knoblach SM, Fan L, Fox GB, Goodnight R, Faden AI. Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. J Neurosci 1997; 17: 7415-7424.
11. Beer R, Franz G, Srinivasan A, et al. Temporal profile and cell subtype distribution of activated caspase-3 following experimental brain injury. J Neurochem 2000; 75: 1264-1273.
12. Knoblach SM, Nikolaeva M, Huang X, et al. Multiple caspases are activated after traumatic brain injury: Evidence for involvement in functional outcome. J Neurotrauma 2002; 19: 1155-1170.
13. Schulz JB, Weller M, Moskowitz MA. Caspases as treatment targets in stroke and neurodegenerative diseases. Ann Neurol 1999; 45: 421-429.
14. Robertson GS, Crocker SJ, Nicholson DW, Schulz JB. Neuroprotection by the inhibition of apoptosis. Brain Pathol 2000; 10: 283-292.
15. Nuttall ME, Lee D, McLaughlin BA, Erhardt JA. Selective inhibitors of apoptotic caspases: Implications for novel therapeutic strategies. Drug Discov Today 2001; 6: 85-91.
16. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Ann Rev Biochem 1999; 68: 383-424.
17. Boyce M, Degterev A, Yuan J. Caspases: An ancient cellular sword of Damocles. Cell Death Differ 2004; 11: 29-37.
18. Wheeler DL, Church DM, Federhen S, et al. Database resources of the National Center for Biotechnology. Nuc Acids Res 2003; 31: 28-33.
19. Fujita E, Jinbo A, Matuzaki H, Konishi H, Kikkawa U, Momoi T. Akt phosphorylation site found in human caspase-9 is absent in mouse caspase-9. Biochem Biophys Res Commun 1999; 264: 550-555.
20. Saleh M, Vaillancourt JP, Graham RK, et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004; 429: 75-79.
21. Nakagawa T, Zhu H, Morishima N, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000; 403: 98-103.
22. Ussat S, Werner UE, Adam-Klages S. Species-specific differences in the usage of several caspase substrates. Biochem Biophys Res Commun 2002; 297: 1186-1190.
23. Juan TSC, McNiece IK, Argento JM, et al. Identification and mapping of Casp7, a cysteine protease resembling CPP32β, interleukin-1β converting enzyme, and CED-3. Genomics 1997; 40: 86-93.
24. Lippke JA, Gu Y, Sarnecki C, Caron PR, Su MSS. Identification and characterization of CPP32/Mch2 homolog 1, a novel cysteine protease similar to CPP32. J Biol Chem 1996; 271: 1825-1828.
25. Denault JB, Salvesen GS. Human caspse-7 activity and regulation by its N-terminal peptide. J Biol Chem 2003; 278: 34042-34050.
26. Srinivisan A, Roth KA, Sayers RO, et al. In situ immunodetection of activated caspase-3 in apoptotic neurons in the developing nervous system. Cell Death Differ 1998; 5: 1004-1016.
27. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998; 273: 32608-32613.
28. Schotte P, Declercq W, van Huffel S, Vandenabeele P, Beyaert R. Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett 1999; 442: 117-121.
29. Lee D, Long SA, Murray JH, et al. Potent and selective non-peptide inhibitors of caspases 3 and 7. J Med Chem 2001; 44: 2015-2026.
30. Kerr LE, McGregor AL, Amet LEA, et al. Mice overexpressing human caspase 3 appear phenotypically normal but exhibit increased apoptosis and larger lesion volumes in response to transient focal cerebral ischaemia. Cell Death Differ 2004; 11: 1102-1111.
31. Cregan SP, MacLaurin JG, Craig CG, et al. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J Neurosci 1999; 19: 7860-7869.
32. Keramaris E, Stephanis L, MacLauren J, et al. Involvement of caspase 3 in apoptotic death of cortical neurons evoked by DNA damage. Molec. Cell Neurosci 2000; 15: 368-379.
33. Kuida K, Zheng TS, Na S, et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 1996; 384: 368-372.
34. Woo M, Hakem R, Soengas MS, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 1998; 12: 806-819.
35. Leonard JR, Klocke BJ, D'Sa C, Flavell RA, Roth KA. Strain-dependent neurodevelopmental abnormalities in caspase-3-deficient mice. J. Neuropathol. Exp Neurol 2002; 61: 673-677.
36. Sambrook J, Russell DW. Molecular Cloning; A Laboratory Manual, 3rd ed. New York: Cold Spring Harbor Laboratory Press 2001.
37. Zheng TS, Hunot S, Kuida K, et al. Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation. Nature Med 2000; 6: 1241-1247.
38. Le DA, Wu Y, Huang Z, et al. Caspase activation and neuroprotection in caspase-3-deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc Natl Acad Sci USA 2002; 99: 15188-15193.
39. Juan TSC, McNiece IK, Jenkins NA, Gilbert DJ, Copeland NG, Fletcher FA. Molecular characterization of mouse and rat CPP32β gene encoding a cysteine protease resembling interleukin-1β converting enzyme and CED-3. Oncogene 1996; 13: 749-755.
40. Pompeiano M, Blaschke AJ, Flavell RA, Srinivasan A, Chun J. Decreased apoptosis in proliferative and postmitotic regions of the caspase 3-deficient embryonic central nervous system. J Comp Neurol 2000; 423: 1-12.
41. Burek MJ, Oppenheim RW. Programmed cell death in the developing nervous system. Brain Pathol 1996; 6: 427-446.
42. Kuida K, Haydar TF, Kuan CY, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998; 94: 325-337.
43. Kuan CY, Roth KA, Flavell RA, Rakic P. Mechanisms of programmed cell death in the developing brain. Trends Neurosci 2000; 23: 291-297.
44. de Bilbao F, Guarin E, Nef P, Vallet P, Giannakopoulos P, Dubois-Dauphin M. Postnatal distribution of cpp32/caspase 3 mRNA in the mouse central nervous system: An in situ hybridization study. J Comp Neurol 1999; 409: 399-357.
45. Momoi T, Fujita E, Urase K. Strain-specific caspase-3-dependent programmed cell death in the early developing mouse forebrain. Neuroreport 2003; 14: 111-115.
46. Urase K, Kouroku Y, Fujita E, Momoi T. Region of caspase-3 activation and programmed cell death in the early development of the mouse forebrain. Dev Brain Res 2003; 145: 241-248.
47. L in developmental programmed cell death. Proc Natl Acad Sci USA 2000; 97: 466-471.